ArticleTransboundary and emerging diseases2026
Discovery of Cetaben as a Novel Antiviral Agent Against Porcine Epidemic Diarrhea Virus From a Cholesterol-Lowering Compound Library.
Article in Transboundary and emerging diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Drug Repurposing as a Broad-Spectrum Strategy Against Coronaviruses: Frontiers in Mechanisms and Clinical Translation.Viruses · 2026Review
- Discovery of Cetaben as a Novel Antiviral Agent Against Porcine Epidemic Diarrhea Virus From a Cholesterol-Lowering Compound Library.Transboundary and emerging diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The devastating impact of porcine epidemic diarrhea virus (PEDV) on the global swine industry underscores an urgent need for effective antiviral therapies. Drug repurposing presents a promising strategy to accelerate the development of such treatments. In this study, we screened a custom-designed library of 117 cholesterol-lowering compounds for anti-PEDV activity using a recombinant PEDV expressing enhanced green fluorescent protein (EGFP). Following two rounds of screening, four compounds exhibiting significant antiviral activity were identified. Among these, cetaben and digitonin displayed superior antiviral efficacy and higher selectivity indices. Subsequent dose-response analyses further confirmed that cetaben effectively suppresses viral replication in both classical and variant strains of PEDV. Time-of-addition assays revealed that cetaben exerts potent antiviral effects primarily at the preinfection stage by inhibiting viral internalization and syncytium formation. Notably, supplementation with exogenous cholesterol in infected cells completely abolished cetaben's antiviral activity and restored viral infectivity, demonstrating that its anti-PEDV mechanism is mediated through disruption of cellular cholesterol metabolism. Collectively, our findings identify cetaben, a cholesterol-lowering agent, as a novel broad-acting antiviral against PEDV with a host-targeted mechanism of action. This study establishes a foundation for developing antiviral strategies that target cholesterol metabolism to combat PEDV and related coronaviruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.